Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Jeffrey V Lazarus^{1

2}, Philip N Newsome³, Sven M Francque^{4

5}, Fasiha Kanwal^{6

7}, Norah A Terrault⁸, Mary E Rinella⁹

Affiliations

¹ CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
² Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
³ National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
⁴ Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
⁵ Laboratory for Experimental Medicine and Paediatrics, InflaMed Centre of Excellence, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
⁶ Sections of Gastroenterology and Hepatology and Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
⁷ VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
⁸ Gastrointestinal and Liver Disease Division, University of Southern California, Los Angeles, California, USA.
⁹ Department of Medicine, University of Chicago, Chicago, Illinois, USA.

Jeffrey V Lazarus et al. Hepatology. 2024.

. 2024 Mar 1;79(3):E93-E94.

doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.

Jeffrey V Lazarus^{1

2}, Philip N Newsome³, Sven M Francque^{4

5}, Fasiha Kanwal^{6

7}, Norah A Terrault⁸, Mary E Rinella⁹

¹ CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
² Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
³ National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
⁴ Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
⁵ Laboratory for Experimental Medicine and Paediatrics, InflaMed Centre of Excellence, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
⁶ Sections of Gastroenterology and Hepatology and Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
⁷ VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
⁸ Gastrointestinal and Liver Disease Division, University of Southern California, Los Angeles, California, USA.
⁹ Department of Medicine, University of Chicago, Chicago, Illinois, USA.

No abstract available

Comment in

Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
Emanuele E, Minoretti P. Emanuele E, et al. Hepatology. 2024 Jan 1;79(1):E4. doi: 10.1097/HEP.0000000000000586. Epub 2023 Aug 30. Hepatology. 2024. PMID: 37651223 No abstract available.

1. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52.
1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.
1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. published online ahead of print, 2023 Aug 2.
1. Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023. published online ahead of print, 2023 Aug 3.
1. Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Chiva Giurca B, et al. Global developments in social prescribing. BMJ Glob Health. 2022;7:e008524.